BETAAccess all features while we're in beta! Some features may become paid later.Send feedback →
vpside

NEOG

Neogen Corp.
Nasdaq · In vitro & in vivo diagnostic substances (SIC 2835) · FY ends 31 May

Revenue, quarterly

$223M+6.5% year on year
$300M$200M$100M$0
Q2 ’22Q3 ’23Q4 ’24Q4 ’25Q1 ’27
Company filings · 10-Q filed 7 Oct 2026 · Q4 = FY − 9Mvpside.com

Gross margin, trailing twelve months

47.4%+1.0 pp year on year
52%50%48%46%44%
Q2 ’22Q3 ’23Q4 ’24Q4 ’25Q1 ’27
Company filings · 10-Q filed 7 Oct 2026 · TTM = last four quartersvpside.com

Cash and cash equivalents, quarter-end

$172M+23.8% year on year
$300M$200M$100M$0
Q2 ’22Q3 ’23Q4 ’24Q4 ’25Q1 ’27
Company filings · 10-Q filed 7 Oct 2026 · balance sheet, period-endvpside.com

Free cash flow, trailing twelve months

$50M
$100M$0−$100M−$200M
Q2 ’22Q3 ’23Q4 ’24Q4 ’25Q1 ’27
Company filings · 10-Q filed 7 Oct 2026 · TTM = last four quartersvpside.com
Chart 05 is empty
Chart 06 is empty